Can Bayer challenge Erleada, Xtandi in prostate cancer? by Carly Helfand Friday, February 15, 2019 For years, J&J and Pfizer-Astellas have been the players in their class of prostate-cancer drugs. But strong new safety data could make Bayer a threat.
Bayer, Geisinger team up for birth control counseling pilot by Beth Snyder Bulik Wednesday, February 13, 2019 Bayer and Geisinger aim to put contraception front and center in women's health visits, starting even before a patient sets foot in the clinic.
PBM giant says 2018 drug cost growth was lowest in 25 years by Eric Sagonowsky Friday, February 8, 2019 Top PBM Express Scripts said that its efforts saved clients $45 billion in 2018, and its clients' drug costs grew just 0.4% last year.
Takeda, new cancer biotech and more—FiercePharmaAsia by Angus Liu Friday, February 8, 2019 Takeda pulls an FDA filing for Ninlaro and is ordered to pay $155 million in a Shire patent case; a cancer startup gets Chinese investors' attention.
Takeda ordered to pay Bayer $155M for patent infringement by Eric Sagonowsky Wednesday, February 6, 2019 A jury ordered Takeda, which just scooped up Shire, to pay $155 million for stepping on Bayer's hemophilia patent.
Bayer gets with the Super Bowl program to kick off cancer push by Beth Snyder Bulik Tuesday, January 29, 2019 Bayer is going to the Super Bowl. Not with some glitzy $5 million TV ad, but instead with a print ad in the official Super Bowl LIII program.
Lartruvo takes a big step back as Lilly aims to beef up in cancer by Eric Sagonowsky Friday, January 18, 2019 Lilly's Lartruvo has been a key launch for its oncology business, but thanks to a phase 3 fail, it plans to stop promoting the drug.
Bayer to shutter Pittsburgh site in global consolidation drive by Angus Liu Wednesday, January 16, 2019 The shutdown means 569 employees and 96 contractors will be cut over the next two years.
Exelixis takes Cabometyx into crowded liver cancer field by Angus Liu Tuesday, January 15, 2019 Exelixis nabbed an FDA nod for Cabometyx in second-line liver cancer, where Stivarga, Opdivo and Keytruda are already battling it out.
M&A boom will hit biopharma in 2019, prognosticators predict by Arlene Weintraub Wednesday, December 19, 2018 The stagnant pharma M&A scene will turn around in 2019, especially with recent declines in biotech valuations, experts predict.
